FORM 4
[ X ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Danson Christopher Joseph 		2. Issuer Name and Ticker or Trading Symbol

Mattersight Corp [ MATR ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
EVP & CHIEF TECHNOLOGY OFFICER
(Last)          (First)          (Middle)

200 W. MADISON, SUITE 3100 		3. Date of Earliest Transaction (MM/DD/YYYY)

8/20/2018
(Street)

CHICAGO, IL 60606
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   8/20/2018     U    158630   D   (1) 0   D    
Common Stock   8/20/2018     U    130257   D   (2) 0   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)   $5.79   8/20/2018     D         115000   (3)   2/27/2012   2/27/2022   Common Stock   115000   $0.00   0   D    
Stock Option (right to buy)   $4.69   8/20/2018     D         50000   (3)   3/15/2013   3/15/2023   Common Stock   50000   $0.00   0   D    
Stock Option (right to buy)   $6.38   8/20/2018     D         56250   (3)   4/21/2014   4/21/2024   Common Stock   56250   $0.00   0   D    
Series B Preferred Stock   $0.00   8/20/2018     U         2356   (4)     (5)   (6) Common Stock   2356     (4) 0   D    

Explanation of Responses:
(1)  Per the terms of the Agreement and Plan of Merger, dated 4/25/18, among the Issuer, NICE Systems, Inc., NICE Acquisition Sub, Inc., and NICE Ltd. (the "Agreement") and the Offer (as defined in the Agreement), each share of the Issuer's common stock was tendered for $2.70 per share in cash, without interest and less any required withholding taxes.
(2)  Per the terms of the Agreement, specified shares of the Issuer's common stock subject to restricted stock award agreements with the Issuer were automatically converted into restricted American depository shares of Nice Ltd.
(3)  Disposed of per Section 2.7(e) of the Agreement, whereby each option with an exercise price greater than $2.70 per share that was outstanding immediately prior to the Offer Closing (as defined in the Agreement) was cancelled without consideration.
(4)  Per the terms of the Agreement and the Offer, each share of the Issuer's Series B Preferred Stock was tendered for $7.80 per share, plus accrued and unpaid dividends payable thereon, in cash, without interest and less any required withholding taxes.
(5)  Immediate
(6)  None

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Danson Christopher Joseph
200 W. MADISON, SUITE 3100
CHICAGO, IL 60606

EVP & CHIEF TECHNOLOGY OFFICER

Signatures
/s/ Corrine N. Taylor, Attorney-in-fact 8/20/2018
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Matria Healthcare (NASDAQ:MATR)
Graphique Historique de l'Action
De Oct 2024 à Déc 2024 Plus de graphiques de la Bourse Matria Healthcare
Matria Healthcare (NASDAQ:MATR)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024 Plus de graphiques de la Bourse Matria Healthcare